Fractyl Health (Nasdaq: GUTS) cuts Q2 costs and reports strong Revita weight-loss durability
Rhea-AI Filing Summary
Fractyl Health, Inc. reported second quarter 2026 results and clinical progress for its obesity and type 2 diabetes programs. For the quarter ended June 30, 2026, research and development expenses were $13.8 million versus $21.2 million a year earlier, and selling, general and administrative expenses were $5.3 million versus $4.9 million. Net loss was $25.5 million compared with $27.9 million, while Adjusted EBITDA was a loss of $16.3 million versus a $24.0 million loss.
As of June 30, 2026, Fractyl held $47.1 million in cash and cash equivalents and expects this to fund operations into early 2027. The balance sheet showed total assets of $82.0 million and a stockholders’ equity deficit of $1.7 million.
Clinically, one-year randomized REMAIN-1 Midpoint Cohort data showed Revita-treated patients in an optimized subgroup maintained about 84% of prior GLP-1-induced weight loss versus 46% with sham, with no device- or procedure-related serious adverse events through one year. Open-label REVEAL-1 data showed maintenance of roughly 78% of GLP-1-induced weight loss. The REMAIN-1 Pivotal Cohort six-month topline readout is expected in early Q4 2026, with a potential FDA De Novo submission in late Q4 2026. Rejuva gene therapy candidate RJVA-001 received Clinical Trial Authorization in the Netherlands and ethics approval in Australia, with first-in-human dosing and preliminary data targeted for the second half of 2026.
Positive
- Operating expenses fell sharply, with total Q2 2026 operating costs at $19.1 million versus $26.1 million, contributing to a smaller net loss and improved Adjusted EBITDA compared with Q2 2025.
- Revita one-year REMAIN-1 Midpoint data showed patients in an optimized group maintained 84% of GLP-1-induced weight loss vs. 46% with sham, with no device- or procedure-related serious adverse events through one year.
- Fractyl reaffirmed key milestones: REMAIN-1 Pivotal Cohort six-month topline data in early Q4 2026 and a potential FDA De Novo marketing application submission in late Q4 2026 for post-GLP-1 weight maintenance.
- Rejuva gene therapy program advanced with Clinical Trial Authorization in the Netherlands and ethics committee approval in Australia for RJVA-001, targeting first-in-human dosing and preliminary data in H2 2026.
Negative
- Fractyl remains highly loss-making, with a Q2 2026 net loss of $25.5 million and a stockholders’ equity deficit of $1.7 million as of June 30, 2026.
- Cash and cash equivalents declined to $47.1 million from $81.5 million at year-end 2025, and the company only projects a cash runway into early 2027, indicating a potential need for additional capital thereafter.
Filing Explained
This August 10 Form 8-K furnishes the company’s second-quarter results and press release as Item 2.02 information, rather than filing that information under Section 18; it communicates the update without making those materials subject to Section 18 liability.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Research and development expenses: $13.8 million
Selling, general and administrative expenses: $5.3 million
Net loss: $25.5 million
+5 more
8 metrics
Research and development expenses
$13.8 million
Quarter ended June 30, 2026; $21.2 million in the same period 2025
Selling, general and administrative expenses
$5.3 million
Quarter ended June 30, 2026; $4.9 million in the same period 2025
Net loss
$25.5 million
Quarter ended June 30, 2026; $27.9 million in the same period 2025
Adjusted EBITDA
$(16.3) million
Quarter ended June 30, 2026; $(24.0) million in the same period 2025
Cash and cash equivalents
$47.1 million
Balance as of June 30, 2026; expected to fund operations into early 2027
Total stockholders’ equity (deficit)
$(1.7) million
As of June 30, 2026; compared with $9.5 million at December 31, 2025
Revita weight maintenance vs sham
84% vs 46%
One-year GLP-1-induced weight loss maintained in optimized REMAIN-1 Midpoint Cohort subgroup
Total operating expenses
$19.1 million
Quarter ended June 30, 2026; $26.1 million in the same period 2025
Key Terms
Adjusted EBITDA, De Novo marketing application, Breakthrough Device designation, Clinical Trial Authorization, +1 more
5 terms
Adjusted EBITDA financial
"Adjusted EBITDA was negative $16.3 million for the quarter ended June 30, 2026"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
De Novo marketing application regulatory
"Potential U.S. Food and Drug Administration (FDA) De Novo marketing application submission in post-GLP-1 weight maintenance"
A de novo marketing application is a regulatory pathway used to get a novel medical device cleared for sale when there is no already-approved similar device to compare it to. It matters to investors because approval allows a company to bring a new product to market without having to show it matches an older device, often shortening the path to sales and creating early competitive advantage, but it also carries regulatory review risk and costs.
Breakthrough Device designation regulatory
"Revita has received FDA Breakthrough Device designation for weight maintenance in people with obesity"
A breakthrough device designation is a regulatory program that gives promising medical devices for serious or life‑threatening conditions priority support and faster review from a health authority (e.g., the U.S. FDA). Think of it as a “fast lane” or VIP pass through development and review: it can shorten time to market, lower regulatory uncertainty, and boost a company’s commercial prospects — but it is not an approval by itself.
Clinical Trial Authorization regulatory
"The platform’s lead candidate, RJVA-001, has received Clinical Trial Authorization in the Netherlands"
A clinical trial authorization is official government permission to begin testing an experimental drug or medical device in people; think of it as a building permit that lets researchers move from planning into real-world testing. For investors, receiving this authorization reduces regulatory uncertainty, unlocks fundraising and milestone payments, and starts a clear timeline of studies whose results can greatly affect a company’s value.
GLP-1-induced weight loss medical
"Revita-treated participants maintained approximately 84% of their GLP-1-induced weight loss compared to 46% in sham participants"
Earnings Snapshot
Net loss: $25.5 million · Guidance included
quarter ended June 30, 2026
Net loss
$25.5 million
Compared with $27.9 million net loss in the quarter ended June 30, 2025
Research and development expenses
$13.8 million
Compared with $21.2 million in the quarter ended June 30, 2025
Selling, general and administrative expenses
$5.3 million
Compared with $4.9 million in the quarter ended June 30, 2025
Adjusted EBITDA
$(16.3) million
Compared with $(24.0) million in the quarter ended June 30, 2025
Cash and cash equivalents
$47.1 million
Compared with $81.5 million as of December 31, 2025
Guidance
The company reiterated cash runway into early 2027 and clinical milestones including REMAIN-1 Pivotal Cohort topline data in early Q4 2026 and a potential FDA De Novo submission in late Q4 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were Fractyl Health (GUTS) key financial results for Q2 2026?
Fractyl reported a net loss of $25.5 million for Q2 2026, versus $27.9 million in Q2 2025. Research and development expenses were $13.8 million and SG&A expenses were $5.3 million, with Adjusted EBITDA a loss of $16.3 million.
How much cash does Fractyl Health (GUTS) have and what is its runway?
As of June 30, 2026, Fractyl had $47.1 million in cash and cash equivalents. Based on current plans, the company believes this cash position will fund operations into early 2027, beyond the anticipated pivotal Revita readout and potential De Novo submission.
What did the REMAIN-1 Midpoint Cohort show for Fractyl Health’s Revita therapy?
In an optimized subgroup, Revita-treated patients maintained about 84% of prior GLP-1-induced weight loss at one year versus 46% with sham. No device- or procedure-related serious adverse events occurred through one year, supporting Revita’s potential in post-GLP-1 weight maintenance.
What upcoming clinical milestones did Fractyl Health (GUTS) highlight for Revita?
Fractyl expects topline six-month randomized data from the REMAIN-1 Pivotal Cohort in early Q4 2026. A potential FDA De Novo marketing application submission for post-GLP-1 weight maintenance is planned for late Q4 2026, with one-year pivotal data targeted in Q1 2027.
How is Fractyl Health (GUTS) progressing its Rejuva gene therapy platform?
Lead candidate RJVA-001 received Clinical Trial Authorization in the Netherlands and ethics approval in Australia. Fractyl plans first-in-human dosing and preliminary data in the second half of 2026, with additional candidates like RJVA-002 remaining in preclinical development.
How did Fractyl Health’s operating expenses change year over year in Q2 2026?
Total operating expenses for Q2 2026 were $19.1 million, down from $26.1 million in Q2 2025. Research and development spending declined to $13.8 million from $21.2 million, while SG&A rose modestly to $5.3 million from $4.9 million.